Special Issue

Machine Learning and Radiomics Applications of MRI-Guided Treatments in Cancers

Message from the Guest Editor

Dear colleagues, Advances in artificial intelligence and machine learning over the recent years including deep learning has spurred a lot of interest and applications of these techniques in several aspects of medicine including cancer diagnosis and treatment. Automated methods for analyzing medical images, including deep learning based detection and segmentation of cancers and normal organs, automated biomarkers for diagnosis and classification of cancer aggressiveness and prediction of outcomes will provide more reproducible and quantitative biomarkers to target and treat cancers. The purpose of this special issue is to highlight the advances in all aspects of machine learning, both deep learning and standard radiomics based machine learning applied to MRI for the purpose of robust detection, prognosis, prediction of response to cancer treatments. Submissions focusing on using MRI for cancer response assessment/prediction, improving robustness and reproducibility of MRI radiomics, classification or segmentation from MRI, and methods combining MRI with other imaging or non-imaging modalities are highly relevant.

Guest Editor

Dr. Harini Veeraraghavan
Department of Medical Physics, Memorial Sloan Kettering Cancer Centre, New York, NY, USA

Deadline for manuscript submissions

closed (30 September 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/65343

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)